Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Castro

Showing results (1-10 of 194) with videos related to

Pageof 20
Sort By:
European Urology Focus|September 5, 2024
PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation CarriersElena Castro
European Urology|December 13, 2021
TP53: Another Piece of the Prostate Cancer Genetics PuzzleElena Castro
Boletin Medico Del Hospital Infantil De Mexico|February 9, 2018
Participation of mesenchymal stem cells in the regulation of immune response and cancer developmentMarta Elena Castro-Manrreza
Clinical Advances in Hematology & Oncology : H&O|February 13, 2014
BRCA mutations in prostate cancer patientsDavid Olmos, Elena Castro
Asian Journal of Andrology|April 24, 2012
The role of BRCA1 and BRCA2 in prostate cancerElena Castro, Rosalind Eeles
Current Problems in Cancer|April 30, 2017
Inherited mutations in DNA repair genes and cancer riskNuria Romero-Laorden, Elena Castro
Translational Andrology and Urology|December 10, 2025
Efficacy at a cost?-quality of life implications of PARP inhibition in the homologus recombination repair (HRR) cohort of TALAPRO-2Jorge Esteban-Villarrubia, Elena Castro
Trends in Molecular Medicine|July 31, 2025
Prostate cancer germline variants with therapeutic implicationsMasoud Bitaraf, Elena Castro, Nima Sharifi
European Urology|February 4, 2025
PARP Inhibitors and Prostate Cancer: The Struggle To Separate the Grain from the ChaffElena Castro, David Lorente, David Olmos
Current Opinion in Urology|March 10, 2022
Implications of DNA damage repair alterations for the management of prostate cancerRebeca Lozano, David Olmos, Elena Castro
Pageof 20

Showing results (1-10 of 194) with videos related to

Sort By:
Pageof 20
European Urology Focus|September 5, 2024
PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation CarriersElena Castro
European Urology|December 13, 2021
TP53: Another Piece of the Prostate Cancer Genetics PuzzleElena Castro
Boletin Medico Del Hospital Infantil De Mexico|February 9, 2018
Participation of mesenchymal stem cells in the regulation of immune response and cancer developmentMarta Elena Castro-Manrreza
Clinical Advances in Hematology & Oncology : H&O|February 13, 2014
BRCA mutations in prostate cancer patientsDavid Olmos, Elena Castro
Asian Journal of Andrology|April 24, 2012
The role of BRCA1 and BRCA2 in prostate cancerElena Castro, Rosalind Eeles
Current Problems in Cancer|April 30, 2017
Inherited mutations in DNA repair genes and cancer riskNuria Romero-Laorden, Elena Castro
Translational Andrology and Urology|December 10, 2025
Efficacy at a cost?-quality of life implications of PARP inhibition in the homologus recombination repair (HRR) cohort of TALAPRO-2Jorge Esteban-Villarrubia, Elena Castro
Trends in Molecular Medicine|July 31, 2025
Prostate cancer germline variants with therapeutic implicationsMasoud Bitaraf, Elena Castro, Nima Sharifi
European Urology|February 4, 2025
PARP Inhibitors and Prostate Cancer: The Struggle To Separate the Grain from the ChaffElena Castro, David Lorente, David Olmos
Current Opinion in Urology|March 10, 2022
Implications of DNA damage repair alterations for the management of prostate cancerRebeca Lozano, David Olmos, Elena Castro
Pageof 20